Background: Intensified TB case finding is recommended for all HIV-infected persons regularly attending HIV care and treatment clinics. The authors aimed to determine how well this system worked among HIV-infected patients diagnosed with presumptive TB in 14 health facilities of Harare province, Zimbabwe, between January and December 2016.
Introduction
Tuberculosis (TB) in sub-Saharan Africa remains largely driven by the Human Immunodeficiency Virus (HIV). Of the 10.4 million new TB cases estimated globally in 2016, 10% were people living with HIV of whom 74% were from Africa. 1 The proportion of TB patients living with HIV was also highest in the World Health Organization (WHO) Africa region at 34% in 2016 compared with 13% globally. 1 This strong association in sub-Saharan Africa between HIV and TB relates to the high prevalence of HIV infection in this part of the world and HIV-related immunosuppression that increases the risk of those with latent TB infection to develop active TB. 2 The introduction of antiretroviral therapy (ART) when administered to HIV-infected patients has improved their survival, 3, 4 and also reduced their incidence of new and recurrent TB. 5 However, despite ART efficacy in improving immune function, supressing viral load and protecting against TB, the incidence of TB is still higher in those HIV-positive even when CD4 cell counts have improved 6 and when compared with those who are HIVnegative. 7 Even with ART, there is an increased risk of mortality, which is strongly associated with prevalent TB at ART initiation and incident TB during ART. 8 This justifies the need to rapidly diagnose, treat and prevent TB prior to and during ART. Given the TB-protective effect of isoniazid preventive therapy (IPT), either alone 9 or in combination with ART, 10, 11 WHO has recommended that countries administer this intervention to HIV-infected persons enrolled within ART programmes, even though it may not completely prevent the development of TB. [12] [13] [14] It is therefore imperative that intensified TB case finding (ICF) be an integral part of HIV care and treatment programmes in order to identify both prevalent and incident TB among those HIV-infected. The WHO recommends ICF among HIV-positive patients enrolled in ART programmes by routinely screening for active TB using the four-symptom checklist at every contact with a health worker followed by TB investigations among those identified as having presumptive TB. 15 Zimbabwe, which has a high HIV prevalence of 14.1% among 15-49-year olds, 16 and a high TB/HIV co-infection rate of 67%, 1 has adopted this screening policy since 2013. ICF has a two-fold benefit of:
• identifying those who have TB and referring them for TB treatment; • identifying those that do not have TB who are potentially eligible for IPT to prevent possible TB disease.
There are, however, operational challenges in screening for TB in HIV care programmes particularly in low resource settings. First, presumptive TB patients upon identification can be lost in the process of referral to a TB clinic for sputum collection especially if the ART and TB clinic services are not integrated in the same setting. Sputum samples collected from presumptive TB patients for direct smear microscopy and/or for Xpert MTB/RIF testing (Cepheid, Sunnyvale, CA, USA) may also be lost. Secondly, the process of tracing patients diagnosed with TB and the eventual initiation of anti-TB treatment may be associated with losses to follow-up along that referral continuum. These losses to follow-up or delays between ICF and TB diagnosis and treatment can lead to worsening disease prognosis among those with TB disease and TB transmission in the community.
The authors therefore assessed the continuum of care among presumptive TB cases enrolled in HIV care, from point of identification as a presumptive TB case to initiation of TB treatment among those diagnosed with active TB. Specific objectives were to describe among HIV-infected patients who were diagnosed as presumptive TB cases in HIV treatment and care settings in Harare province, Zimbabwe:
• their demographic and clinical characteristics at the point of being classified as presumptive TB; • the number and proportion that had sputum samples collected and sent for laboratory diagnosis, were diagnosed with TB and eventually started on TB treatment; • the time taken from the presumptive TB screening episode to initiation of TB treatment.
Methods

Study design
A retrospective cohort study using routinely collected data.
Setting
The Harare City health department, located in Harare City (Zimbabwe's capital), has 38 health facilities that serve the Harare urban area with a population of approximately 1 485 000. 17 This current study was conducted in 14 of these health facilities in Harare where presumptive TB cases are recorded in a patient-level HIV electronic database system (ePMS), as well as in paper-based records. The ePMS system is available at selected ART clinics countrywide. Designated data entry clerks enter data into the ePMS after abstracting information from individual patient HIV care booklets at enrolment and every subsequent review visit. Of the 14 health facilities, two are infectious disease hospitals, four are satellite clinics, while the remaining eight are polyclinics. All 14 selected health facilities offer HIV testing services, TB screening and treatment, and HIV treatment and care services free of charge as part of curative services. 18 HIV treatment and care services and intensified TB-case finding in Zimbabwe
All HIV-infected patients in Zimbabwe are enrolled into HIV treatment and care services for ART initiation after receiving a confirmed HIV-positive result either through client-initiated (onsite or off-site) or provider-initiated HIV testing services countrywide. Since 2013, in line with WHO Guidelines, 19 ART has been initiated in HIV-infected adults and adolescents with CD4 cell count ≤500 cells/mL where a CD4 count is available. ART was also initiated regardless of CD4 count for those HIV-infected patients who:
• had WHO clinical stage 3 or 4;
• were pregnant or lactating women;
• were in HIV sero-discordant (SD) couple relationships;
• were TB or hepatitis co-infected;
• were under 5 years of age.
Beginning in 2016, selected districts started implementing the HIV 'TREAT ALL' approach in line with the adapted national consolidated HIV guidelines, 20 and since 2017 this has been scaled-up countrywide. The preferred first-line ART regimen for adults, adolescents, and older children is tenofovir, lamivudine and efavirenz (600), while zidovudine, lamivudine and nevirapine are the alternative first-line regimen.
According to national guidelines, 21 all HIV-infected individuals should be screened for TB at their routine 2-3-monthly clinic review and pill pick-up visits using the WHO recommended four-symptom TB screening checklist. This checklist includes current cough, fever, night sweats and loss of weight. Anyone with one or more of these symptoms is considered to have presumptive TB, which is recorded in individual patient opportunistic infection/ART care booklets, as well as in the presumptive TB case register, which is located in the HIV treatment and care clinic or alternatively in the TB clinic and later entered into the ePMS.
Presumptive TB patients should submit two spot sputum samples during the same day in order to reduce chances of patients being lost to follow-up. These are sent to a TB diagnosis centre either on-site or at another health facility in the district for TB investigations. Within Harare City health department, TB diagnosing centres are located at its two infectious disease hospitals and all polyclinics, while satellite clinics and family health service clinics submit their samples to TB diagnosing centres closest to them. HIV-positive patients found not to have Transactions of the Royal Society of Tropical Medicine and Hygiene symptoms or signs of active TB disease when screened for eligibility for isoniazid preventive therapy (IPT), undergo adherence counselling before being started on a daily dose of 300 mg of isoniazid (isonicotinic acid hydrazide (INH)) plus low dose pyridoxine (25 mg) for a period of 6 months, in line with national IPT guidelines. 12 During IPT and ART resupply visits, patients continue to be screened for TB, and if found to have active TB they are discontinued from IPT, have a sputum sample collected for culture and drug susceptibility testing (DST) and subsequently started on full anti-TB treatment. In general, health care workers undertake a 2-week HIV integrated training (HIT), as part of continuing professional development where they learn about the reasons and practice of intensified TB case finding.
Tuberculosis diagnosis and management in Zimbabwe
TB diagnosis among the HIV-infected presumptive TB cases is made preferably through an Xpert MTB/RIF assay or through direct sputum smear examination for acid-fast bacilli with a ZiehlNeelsen stain where the Xpert MTB/RIF instrument is unavailable. Bacteriologically confirmed PTB cases are those whose sputum smears are positive for acid-fast bacilli or Xpert MTB/RIF positive for Mycobacterium tuberculosis. They are immediately traced and started on anti-TB treatment upon receipt of their results at the health facility. If Xpert MTB/RIF is used as the initial TB test, those who show rifampicin resistance have their second sputum specimen sent to one of the country's two national reference laboratories for culture and DST. Those with negative smears are normally referred to the Medical Examination Centre (MEC) at one of the Harare City health department hospitals (Beatrice Road Infectious Disease hospital) in the event that the clinician still has a strong suspicion of TB. At the MEC, they are seen by a doctor and undergo a chest X-ray, which if suggestive of TB results in a diagnosis of smear-negative PTB. Extra-pulmonary TB (EPTB) can also be diagnosed on clinical grounds with circumstantial evidence along with supporting specific diagnostic tests. 21 Smear-negative and EPTB patients are started on TB treatment at the MEC and referred back to their health facilities where they receive ART during their TB treatment.
Study population
The study included all HIV-positive patients who were enrolled in ART clinics of 14 health facilities under the Harare City health department and who were identified as having presumptive TB between 01 January 2016 and 31 December 2016.
Data variables, sources of data and data collection
The list of enrolled HIV-infected patients and those with presumptive TB recorded between 1 January 2016 and 31 December 2016 was obtained from the ePMS, which was available in all the 14 health facilities selected in this study. All presumptive TB cases listed from the ePMS were then traced and matched by name, sex and age with data recorded in the presumptive TB registers at their respective facilities, since there is no unique identifier linking the two data sources.
Information in the presumptive TB register was then matched with that in the laboratory registers and eventually the TB registers for those diagnosed with bacteriologicallyconfirmed TB, using the presumptive TB client number. Those with negative smears were traced in the records at the MEC in order to determine whether they were diagnosed with smearnegative PTB or EPTB and started on anti-TB treatment. All recorded presumptive TB cases were traced for a period of 3 months after the date of being identified as presumptive TB to accommodate delays in sputum collection, laboratory diagnosis and commencement on anti-TB treatment. Presumptive TB patients documented in the ePMS were also searched for in the laboratory and TB treatment registers if they were not identified in the presumptive TB register. Once patients were traced, data were collected using a structured proforma on demographic and clinical characteristics, laboratory diagnosis, type and category of TB along with dates of registration, sputum sample collection and receipt, and diagnosis and start of anti-TB treatment.
Analysis and statistics
Data were double-entered by two data entry clerks into Epidata version 3.1 (Epidata Association, Odense, Denmark), and cleaned and analysed using Stata version 13.0 (Stata Corporation, College Station, Texas) statistical software. Univariate analysis included tabulating frequencies and proportions for categorical variables, and medians and interquartile ranges for skewed continuous variables such as age, CD4 cell counts and time intervals from recording as a presumptive TB case to TB diagnosis and treatment commencement. Unadjusted and multivariate-adjusted logistic regression was used to determine odds ratio and their 95% confidence intervals for the primary outcome, pre-TB diagnosis lost-tofollow-up (LTFU). Pre-TB diagnosis LTFU was defined as any recorded presumptive patient who was not traceable in the laboratory registers and at the MEC and therefore assumed not to have had follow-up TB investigations done. P-values <0.05 were considered statistically significant.
Ethics
Ethical approval was obtained from the Medical Research Council of Zimbabwe (MRCZ) and from the Ethics Advisory Group (EAG) of the International Union Against TB and Lung Disease, Paris, France. Permission to access data from health facilities was obtained from the Harare City Health Department. Names of patients and addresses were omitted during data entry in order to ensure anonymity and confidentiality.
Results
Of 47 659 HIV-infected patients cumulatively registered at the 14 health facilities by end of December 2016, there were 102 (<1%) patients who were recorded as presumptive TB during that calendar year. Their demographic and clinical characteristics are shown in Table 1 . Study participants had a mean age of 37 years (standard deviation (SD), 12) and the majority were female 58% (59/102). The majority were receiving ART (94%) Figure 1 illustrates the distribution of identified presumptive TB cases who received follow-up TB investigations and those started on anti-TB treatment. Of the 102 patients identified in the ePMS, only 23% (23/102) were recorded in the presumptive TB register and of these, 65% (15/102) were traced to the laboratory registers at their health facilities' respective TB diagnosing centres. Of the 79 patients not recorded in the presumptive TB register, 9% (7/79) were traced to the laboratory registers. Of the 22 patients whose sputum samples were recorded in the laboratory registers, none was found to be positive on smear microscopy. Of these, 45% (10/22) had an Xpert MTB/RIF assay and one was found to be positive. The patient with a positive MTB/RIF result was not traced in the TB treatment register and, therefore, was not documented as starting anti-TB treatment. Of the nine patients with a negative MTB/RIF result, 56% (5/9) were started on anti-TB treatment. One other patient was started on anti-TB treatment without being traced in the laboratory register, making a total of six patients started on treatment.
The median time from being identified as presumptive TB to starting TB treatment, and for each of the various steps, is shown in Table 2 . The overall median time from recording in the ePMS as a presumptive TB case to start of TB treatment in the six patients was 12 days (IQR, 7-69). Of those who were recorded in the presumptive TB register, entry of this information was done on the same day that they were recorded as a presumptive TB case. Median time from being recorded in the presumptive TB register to receipt of sputum samples at the laboratory was 2 days (IQR, 0-2).
Demographic and clinical characteristics associated with loss to follow-up for patients identified in the EPMS, but not being documented in the laboratory register are shown in Table 3 . After adjustment for cofounders, the only significant factor that increased the risk of not making it to the laboratory register was not being recorded in the presumptive TB register.
Discussion
This is the first study from Zimbabwe assessing the performance of the routine programmatic system for managing HIV-infected patients identified as presumptive TB within HIV treatment and care services in Harare. The findings were not encouraging. The number of presumptive TB cases amongst patients in HIV care was low at less than 1%. Less than a quarter of the patients registered in the ePMS as having presumptive TB were registered in the paper-based health facility presumptive TB register. About one-fifth of all the patients with presumptive TB had sputum samples received at a diagnostic laboratory, this event being significantly higher for those patients listed in the presumptive TB register. Of the sputum samples received, none were sputum-positive for acid-fast bacilli. Less than half of these had Xpert MTB/RIF assays performed and, where it was done, only one assay was positive and there was no documentation to confirm that this patient was started on anti-TB treatment. There was a total of six patients started on TB treatment, presumably on clinical and radiographic grounds, as for five of them none of their sputum smears or Xpert MTB/RIF assays were positive for TB, and for the other there was no record of the patient being in the laboratory register. Finally, the only significant factor that increased the chance of patients having sputum samples received at a diagnostic laboratory was being listed in the presumptive TB register.
An important strength of this study was the use of routine programme data, which reflected how recommended national policies and guidelines were implemented in real life settings. The authors also adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for the conduct and writing up of this study. 22 There were, however, some limitations. First, there were incomplete records, which may have resulted in an incorrect assumption that whatever was not documented was therefore not done. Secondly, the process of matching data on TB Transactions of the Royal Society of Tropical Medicine and Hygiene screening episodes that were entered in the ePMS with data recorded in the presumptive TB registers and laboratory registers by name was difficult; this might have resulted in missed cases and, therefore, an overestimate in patients who were LTFU before laboratory investigations were done. Thirdly, there is no way of knowing if all patients enrolled in HIV care and were subsequently followed-up were truly screened for TB at every clinic visit, nor how comprehensive or reliable the screening process was, when using the four-symptom check list. Fourthly, there were missing data on dates for sputum collection, for submission to the laboratory and return of results, hence limiting the findings on times taken for the screening process. Finally, while this study was conducted within the routine health system in an urban setting, the findings may not be representative of more rural settings.
It is necessary to question whether the few HIV-infected patients identified with presumptive TB truly reflect the number with TB-related symptoms. A systematic review and metaanalysis of TB screening amongst people living with HIV found a median prevalence of new TB at 8.6% in ART and medical clinics in sub-Saharan Africa, 23 which suggests that there should be much higher rates of presumptive TB. This raises concerns about whether intensified TB screening in this setting is being done routinely and effectively, concerns that are justified in the light of a recent study from South Africa pointing to enormous gaps in the routine practice of TB screening in primary health care facilities in that country. 24 Alternatively, low rates of presumptive TB could be due to the years of national scale-up of IPT in HIV-infected patients in Zimbabwe, which in turn could have decreased the incidence of both presumptive and diagnosed Figure 1 . Flowchart of TB diagnosis and anti-TB treatment initiation among presumptive TB patients identified in HIV care in Harare City health department clinics from January to December 2016. TB, tuberculosis; smear -ve or Xpert -ve, tests negative; Xpert +ve, Xpert MTB/RIF assay positive for Mycobacterium tuberculosis. Of 22 patients who submitted sputum samples, 14 (64%) submitted two and eight (36%) submitted one sample.
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TB.
1 Answers to this question will require further in-depth research.
As this was a study using previously collected secondary data, it was only possible to speculate about the causes of the system failure. While there has been integration of TB/HIV services countrywide resulting in the provision of HIV testing services and follow-up linkage to ART care in TB settings and screening of TB symptoms among clients in ART care, there still remain existing gaps. A high proportion of patients with presumptive TB had no TB diagnostic test performed or recorded, findings similar to a recent report about screening and diagnosis of TB in primary health care clinics in South Africa. 24 This may have been due to:
• poor referral of identified presumptive TB cases for registration in the presumptive TB register; • poor sputum collection;
• long lines of patients in the clinics impeding health care workers from documenting screening results and giving proper information to patients about referral for TB investigations.
It is possible, although not ideal, that these patients may have sought TB investigation, diagnosis and treatment from other health facilities, and hence were missed in this study. Better qualitative research is needed in order to answer these questions. Why all patients were not listed in the presumptive TB register, which was the one factor significantly improving the referral of patients to the laboratory, is not known, but patients may not have appeared at the TB diagnostic site where some of the registers were kept. There were also anecdotal reports of register shortages during the study period.
It was observed that just over one-third of patients only submitted one sputum sample instead of two (again the reasons why are not known), and this may have resulted in an underdiagnosis of TB of up to 10% using smear-microscopy. 25, 26 The rate of under-diagnosis may be even higher in HIV-infected patients who are known to present a pauci-bacillary picture due to immunosuppression. 27 The reason for a large proportion of smear-negative patients failing to have Xpert MTB/RIF assays performed is not known, and this is despite the assay being well known for increased diagnostic sensitivity. 28 There are some important implications arising from this study. First, it is essential moving forward that all health facilities have a presumptive TB register at different entry points, such as the outpatient departments, maternal and child health clinics, ART clinics and the TB clinics. Also, as part of regular quarterly supervision the numbers of patients being listed in the ePMS need to be checked against the numbers listed and documented in the presumptive TB registers. Initiating quality-improvement projects, which are increasingly being adopted in the HIV programme in Zimbabwe for low-performing indicators at various levels of health care, will be important for improving this area of the intensified TB case finding and IPT programme, given their positive impact through using the Plan-Do-Study-Act cycles. 29 This may help to reduce the numbers of missing patients and may help to improve their individual prognosis, as well as reduce TB transmission in ART clinics. Furthermore, this calls for the need to develop an electronic patient management system for the TB programme, which can be linked to the ePMS for easy and regular follow-up of recorded presumptive TB cases in the ePMS.
Secondly, based on the adage of 'what gets measured gets done', it will be important to ensure that all presumptive TB patients in the register and the ePMS have an outcome-either of having started on anti-TB treatment, started on IPT or having had no decision made. Proper documentation can also be a way of ensuring good compliance with screening for IPT and avoiding the risk of mistakenly starting patients with active TB on isoniazid, which would increase the risk of developing isoniazid mono-resistance. 30 Thirdly, the low utilization of Xpert MTB/RIF may limit first the detection of TB, given its higher sensitivity when compared with smear microscopy, and secondly the detection of multi-drug resistant TB, which may be more prevalent among HIV-infected patients. 31 Xpert MTB/RIF has its limitations in that the assay cannot identify isoniazid resistance, which currently requires culture and drug susceptibility testing or a line probe assay. Despite these limitations, replacement of smear microscopy with Xpert MTB/RIF as the initial diagnostic test is now adopted by WHO and Zimbabwe, and this may lessen time delay to treatment initiation, particularly for those who are smear-negative and have to undergo antibiotic treatment and chest X-ray examination at another referral hospital. 
Transactions of the Royal Society of Tropical Medicine and Hygiene
Conclusions
This study shows that the current system in Harare province of Zimbabwe about referring HIV-infected patients in ART clinics with presumptive TB for diagnosis and start of anti-TB treatment functions poorly, with losses to follow-up at each of the steps. Ways to improve this are discussed that include the provision of presumptive TB registers at all health facility entry points (particularly the ART clinic) and making better use of the Xpert MTB/RIF assay.
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